Loading stock data…
$28.14-0.57 (-1.99%)
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
Immunovant, Inc. in the Healthcare sector is trading at $28.14 with a market capitalization of $7.7B. Wall Street consensus targets $48.88 (16 analysts), implying a +73.7% move over the next 12 months. The stock is currently 38% below its 52-week high of $45.42, remaining 11.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$160.32M↓ | -$159.55M↓ | -$114.36M↑ | -$131.76M↓ | -$127.22M |
| Net Income | -$153.22M↓ | -$147.86M↓ | -$110.64M↑ | -$126.50M↓ | -$120.61M |
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for gr...